Ghisallo Capital Management LLC acquired a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 50,000 shares of the company’s stock, valued at approximately $1,381,000. Ghisallo Capital Management LLC owned approximately 0.09% of Protagonist Therapeutics as […]
Capital One Financial assumed coverage on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a research note released on Monday, MarketBeat.com reports. The brokerage issued an overweight rating and a $32.00 price target on the stock. Capital One Financial also issued estimates for Protagonist Therapeutics’ Q3 2023 earnings at ($0.68) EPS, Q4 2023 earnings […]
Gratus Capital LLC lifted its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 3.7% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 219,586 shares of the company’s stock after purchasing an additional 7,855 shares during the quarter. Gratus […]
StockNews.com lowered shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) from a hold rating to a sell rating in a research report released on Wednesday. PTGX has been the topic of several other reports. JMP Securities lifted their target price on Protagonist Therapeutics from $28.00 to $35.00 in a report on Thursday, July 6th. HC […]
HC Wainwright reaffirmed their buy rating on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a report released on Tuesday morning, Benzinga reports. They currently have a $38.00 price objective on the stock. A number of other research analysts also recently issued reports on the stock. StockNews.com downgraded shares of Protagonist Therapeutics from a […]